Holistic Patient Safety: Reframing Technology’s Role in Safer Clinical Trials

Written by:
Andrea Bastek, VP Market Strategy, Florence Healthcare

Patient Safety Awareness Week (March 9–15, 2026) is a powerful reminder that patient protection is the foundation of clinical research, and it’s worth asking:

Are we thinking about patient safety holistically?

Too often, safety is reactively assessed through downstream mechanisms such as adverse event reporting, monitoring activities or safety committee oversight. While these tasks are essential, the responsibility for patient safety begins much earlier, at the study planning phase, and continues through site selection, protocol execution and operational oversight. When approached strategically, technology can serve as a critical element of patient safety.

As sponsors, CROs, sites and technology vendors navigate an increasingly complex, global and digitally enabled research landscape, three interconnected ideas will help proactively improve patient safety:

1. Designing with patients, not just for them
2. Strengthening execution through connected oversight and operational intelligence
3. Deploying AI responsibly within clear regulatory guardrails

Designing for Safety: Access, Trust, and Upstream Patient Voice

Participant “Recruitment & Retention” has ranked among the most significant challenges for clinical research sites of all sizes and across all geographies for the last three years according to the WCG Clinical Research Site Challenges Report^1,2. “Patient Access Challenges (Postponed Visits, Patient Travel, etc.)” also rank in the top 10 issues for research sites^1,2. These challenges are multi-faceted, of course, but they are certainly compounded by the complexity of trials, the perception and fear of potential safety risks, the lack of trust in the system and the logistical burden to attend visits. Missed visits, incomplete follow-ups and study withdrawals compromise both data integrity and participant safety.

The limited availability of clinical trials further compounds these issues. A recent analysis published in JCO Oncology Practice found that the number of oncology clinical trial sites has decreased since 2017 and more than 70% of U.S. counties have no oncology clinical trials³. For patients in these regions, limited access to research may restrict potentially life-extending treatment options, which is a patient safety concern in its own right.
Sponsors and CROs must continue to consider these challenges that impact patient safety farther upstream, during study design, operational planning and site selection. Structured patient advisory engagement, real-world data analysis, and early stress-testing of consent form language⁴, inclusion criteria and visit schedules can surface friction before first patient in. Designing studies that reflect lived experience reduces avoidable dropout and strengthens compliance.

Strengthening Execution: Digital Infrastructure and Real-Time Oversight

Fragmented systems, siloed documentation and manual workflows delay visibility into data, creating vulnerabilities that scale quickly in global trials. For CROs coordinating many studies across hundreds or thousands of sites, small inconsistencies can compound into meaningful safety risks.

This is where digital infrastructure becomes a patient safety asset.

Connected systems or data streams improve transparency and reduce manual handoffs. When data flows in near real time research teams gain earlier visibility into emerging risks. Risk-Based Quality Management (RBQM) provides a framework for this proactive oversight⁵, leveraging centralized analytics to detect patterns such as:

• Increased protocol deviations at specific sites.
• Delays in data entry or query resolution.
• Missed or rescheduled visits.
• Incomplete documentation trends.

These operational indicators often precede safety events. Early identification allows CROs and sponsors to intervene before issues escalate.

In addition to improving informed consent content⁴, the informed consent process can also benefit from digitization by supporting:

• Centralized version control
• Timely re-consent following amendments
• Clear documentation trails
• Consistent deployment across sites

The goal is to reduce administrative burden and ensure quality and compliance while allowing more time for the critical human interaction that defines the consent process. A digital consent process also improves central oversight and the early detection of patient safety issues.

Responsible Innovation: AI and Regulatory Alignment

Artificial intelligence is increasingly being adopted in clinical trials. A recent survey of clinical trial technology showed 34% of respondents “Piloting” or “Consistently Using” AI across a range of workflows from document drafting to record review and quality oversight⁶.

Regulators have made clear that innovation is welcome and it must be paired with governance. In 2026, the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) issued joint principles on the use of AI in medicine development and regulation, emphasizing transparency, explainability, human oversight, risk management, and accountability⁷. For CROs and technology partners, this reinforces an important principle: AI should augment expertise, not replace it.

When deployed responsibly, AI can support patient safety by:

• Assisting with plain-language drafting for participant-facing materials.
• Identifying inconsistencies across trial documentation.
• Highlighting operational bottlenecks through predictive analytics.
• Enhancing centralized RBQM dashboards.

As AI tools mature they may also improve the process of creating content for patient-facing materials to support the recruitment and consent processes, making clarity and accessibility easier to achieve without increasing staff workload.

However, AI outputs that influence participant-facing materials or operational decisions require validation and human review with clearly defined guardrails.

Designing Safety Into the System

Patient Safety Awareness Week is an opportunity to expand the lens through which safety is viewed. Patient safety does not start with the first adverse event report. It starts with how we plan to design, execute, and govern clinical research from the very beginning. Technology can support this holistic approach and shift from reactive detection to proactive intervention.

References

1. WCG. 2024 Clinical Research Site Challenges Report. https://www.wcgclinical.com/wp-content/uploads/2024/10/WCG_2024_Clinical_Research_Site_Challenges_Report.pdf
2. WCG. 2025 Clinical Research Site Challenges Report. https://www.wcgclinical.com/wp-content/uploads/2025/10/siteChallengesReport25__final.pdf
3. Kirkwood MK, et al. State of Geographic Access to Cancer Treatment Trials in the United States: Are Studies Located Where Patients Live? JCO Oncology Practice: 21(3), 427-437, 2025. https://ascopubs.org/doi/10.1200/OP.24.00261
4. From Compliance to Comprehension: Advancing Patient-Centered Informed Consent in Clinical Research. CISCRP, 2025. https://www.ciscrp.org/from-compliance-to-comprehension-advancing-patient-centered-informed-consent-in-clinical-research
5. Stansbury N, et al. Risk-Based Quality Management: A Case for Centralized Monitoring. Ther Innov Regul Sci: 59(2):199-210, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC11880074/
6. Florence Healthcare. 2026 State of Clinical Trial Technology Report. https://www.florencehc.com/downloads/2026-state-of-clinical-trial-technology-report/
7. EMA and FDA set out common principles for AI in medicine development. EMA & FDA, 2026. https://www.ema.europa.eu/en/news/ema-fda-set-common-principles-ai-medicine-development-0